| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
87,080,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Co.'s compound, batoclimab, is a human, monoclonal antibody targeting the neonatal fragment crystallizable receptor. Co.'s product candidate, batoclimab, has been dosed in small volumes (e.g., two mL) and with a 27-gauge needle, while still generating therapeutically relevant pharmacodynamic activity. Co. is developing batoclimab for Myasthenia Gravis, Thyroid Eye Disease and Warm Autoimmune Hemolytic Anemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,526,316 |
1,977,983 |
| Total Buy Value |
$0 |
$0 |
$58,000,008 |
$60,700,210 |
| Total People Bought |
0 |
0 |
1 |
3 |
| Total Buy Transactions |
0 |
0 |
1 |
4 |
| Total Shares Sold |
121,451 |
211,093 |
494,767 |
657,606 |
| Total Sell Value |
$3,709,409 |
$7,040,317 |
$13,330,723 |
$15,815,635 |
| Total People Sold |
7 |
10 |
10 |
10 |
| Total Sell Transactions |
16 |
30 |
46 |
72 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Yanchik Connealy Pamela |
Chief Financial Officer |
• – – |
2021-03-19 |
4 |
A |
$0.00 |
$0 |
D/D |
46,200 |
46,200 |
|
- |
|
| Fromkin Drew J |
Director |
– • – |
2021-03-19 |
4 |
A |
$0.00 |
$0 |
D/D |
15,500 |
40,200 |
|
- |
|
| Torti Frank |
Director |
– • – |
2021-03-19 |
4 |
A |
$0.00 |
$0 |
D/D |
19,200 |
47,600 |
|
- |
|
| Migausky George V |
Director |
– • – |
2021-03-19 |
4 |
A |
$0.00 |
$0 |
D/D |
15,500 |
60,200 |
|
- |
|
| Jain Rita |
Chief Medical Officer |
• – – |
2021-03-19 |
4 |
A |
$0.00 |
$0 |
D/D |
109,365 |
129,365 |
|
- |
|
| Elliott Michael James |
Chief Scientific Officer |
• – – |
2021-03-19 |
4 |
A |
$0.00 |
$0 |
D/D |
97,600 |
97,600 |
|
- |
|
| Pande Atul |
Director |
– • – |
2021-03-19 |
4 |
A |
$0.00 |
$0 |
D/D |
15,500 |
40,200 |
|
- |
|
| Hughes Douglas J. |
Director |
– • – |
2021-03-19 |
4 |
A |
$0.00 |
$0 |
D/D |
15,500 |
40,200 |
|
- |
|
| Salzmann Peter |
Chief Executive Officer |
• • – |
2021-03-19 |
4 |
A |
$0.00 |
$0 |
D/D |
132,500 |
132,500 |
|
- |
|
| Jain Rita |
Chief Medical Officer |
• – – |
2021-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
|
- |
|
60 Records found
|
|
Page 3 of 3 |
|
|
